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Targeted radionuclide therapy (TRT) targeting prostate-specific membrane 
antigen (PMSA) has been introduced in the cutting-edge clinical field of prostate 
cancer therapy. The effectiveness of TRT depends primarily on the total absorbed 
dose of the tumor and normal tissues. Therefore, available range of radioactivity dose, 
above the tumor lethal dose and below the maximum safety dose, must be 
determined as accurately as possible. Due to the various limitations associated with 
organ level dosimetry, the voxel-based dosimetry has become essential for the 
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assessment of more accurate absorbed dose during TRT. The main purpose of this 
study is to compare between radiation exposure of PSMA-targeting peptide and 
albumin-based nanoparticle to the normal tissue using voxel-based dosimetry 
method.  
In this study, PSMA targeting radiolabeled peptide (64Cu-GUL) and albumin-
based nanoparticle (64Cu-albumin-GUL) were synthesized and voxel-based 
dosimetry was performed with PET/CT images of normal mice using direct GATE 
MC simulation.  
The absorbed doses are higher in mice treated with 64Cu-albumin-GUL than in 
mice treated with 64Cu-GUL in all of the brain, heart wall, lungs, liver and kidneys. 
64Cu-GUL was mainly accumulated in the kidneys and 64Cu-albumin-GUL were 
accumulated in the liver. Residence time of 64Cu-albumin-GUL in the blood was 
also higher than that of 64Cu-GUL. 
Single peptide 64Cu-GUL leads higher radiation exposure to the kidneys and 
albumin-based nanoparticle 64Cu-albumin-GUL increases overall radiation exposure 
to the normal tissue due to its long blood circulation, which should be taken into 
consideration for optimal TRT. 
 
Keywords: voxel-based dosimetry, GATE, 64Cu-GUL, 64Cu-albumin-GUL, PET/CT, 
PSMA  
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Single peptide vs. albumin nanoparticle for TRT 
 
Targeted radionuclide therapy (TRT) has great importance for the treatment of 
various cancers such as lymphoma, neuroendocrine tumors and recently, prostate 
cancer (1, 2). It is the basis for successful TRT that radiopharmaceuticals reach the 
lethal dose within the target tissue selectively with minimal toxicity to the 
surrounding normal tissue (3). And choosing an ideal clearance mechanism is one 
of the important factors in the design of TRT. Rapid clearance and short circulation 
time lead minimal background activity. Slow clearance and long circulation time 
allows greater accumulation in the target sites. And particle size plays a key role in 
clearance from the body. Small particles (<10 nm) is cleared through renal excretory 
system and larger particles (>10 nm) is cleared through the liver and the 
mononuclear-phagocyte system, which is relatively slow (4).   
Small molecular type is thought to have effective targeting efficacy based on 
their lower molecular weight and higher permeability. Fast clearance of radiolabeled 
small molecules from the blood pool leads low background activity, which is 
beneficial. However, too rapid renal clearance during short time could be a hurdle 
with concerns about limitation of being taken up by the target organ after first-pass 
distribution and radiation exposure to the kidneys (5).  
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Nanoparticles conjugated with target peptide molecules generally has 
prolonged blood circulation time and be expected to have effective targeting efficacy 
because it has adequate time to reach and bind the target cell. And it has a large 
surface area that can be versatile by various surface modification method.  
Albumin was introduced to be a suitable nanoparticle without significant side 
effect because it is naturally existed molecules in the human body (6). It is nontoxic, 
non-immunogenic and biocompatible. Human serum albumin is consists of a single 
chain 585 amino acid protein with a molecular weight of 66.5 kDa and escapes renal 
filtration due to its size above the threshold for renal clearance (7). And also, its pH-
dependent interaction with the neonatal Fc receptor (FcRn) is known to have 
protective role from intracellular degradation (8, 9). Therefore, it has exceptionally 
long blood circulation time with approximate half-life of 19 days in human serum 
compared with other circulating proteins (7, 10, 11). Many early researchers has 
attracted to these properties of the albumin as a carrier for drug delivery while 
assuming that albumin-based nanoparticle gives an adequate time to reach target 
organ. Since Abraxane, a FDA-approved albumin-based nanomedicine for 
metastatic breast cancer, successfully proved that albumin is a clinically applicable 
nanoparticle, albumin gets a lot attention from many researchers (12, 13). In nuclear 
medicine field, albumin has been radiolabeled to be used for blood pool imaging. 
But in the case of high radionuclide dose for therapy, high radioactivity in blood pool 




Voxel dosimetry with PET/CT for TRT 
 
Only for nuclear medicine imaging, radiation exposure to the normal tissue is not 
a critical radiobiological concern. However, in terms of TRT, it is always better for 
the absorbed dose to be determined as accurately as possible. And to know the 
maximum safe dose is one approach to set administered radiopharmaceutical dose.  
The method called MIRD, Medical Internal Radiation Dose, has conventionally 
been used for estimation of absorbed doses at the organ level (14). This method 
assumed a homogenous distribution of radioactivity in each organ and a generalized 
geometry using S-value, which is mean absorbed dose in a target organ per 
radioactivity decay in a source organ. So, it has inherent limitation in dose estimation 
due to anatomical diversity and variable radioactivity distributions. 
Voxel-based dosimetry using Monte Carlo (MC) simulation is considered to 
produce the more realistic dose distribution in the organs at the voxel-level with high 
precision since it reflects actual tissue heterogeneity and radioactivity distribution in 
the whole body (15). Therefore, to determine upper limit of injected radioactivity 
below normal tissue toxicity for TRT, voxel-based dosimetry is preferable.  
Copper-64 (64Cu), one of the well-known long-lived positron emitter with a half-
life of 12.7 hours, has emerged as a promising radionuclide for imaging and therapy. 
From the physical aspect, 64Cu has valuable characteristics that make it a 
multipurpose radionuclide (16, 17). It has a so complex decay scheme, which is 
simultaneous emission of positron and beta minus radiations that it can be used both 
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for diagnostics and therapeutic purposes. Not only the positron emission (17.4%) 
without abundant gamma emission allows high resolution PET images but also beta 
emission (39%) allows therapeutic potentials with a high local radiation dose at the 
cellular level. Besides, the emission of Auger electrons, associated with the electron 
capture decay (43%) add the therapeutic effectiveness once the radionuclide is 
internalized inside the cells and located within or close to the nucleus. Therefore, 
64Cu is a promising radionuclide having a potential to be used for TRT to enable 
accurate dosimetry using PET imaging during therapy. 
 
PSMA-targeting TRT for prostate cancer 
 
Prostate cancer is the most frequently diagnosed male cancer in many countries 
(18) and 5th common male cancer in Korea in 2015 with constant increasing trends 
for the whole period from 1983 to 2015 (19). The prostate-specific membrane 
antigen (PSMA) is a type II membrane glycoprotein and is primarily expressed in 
the normal human prostate epithelium (20). Because PSMA is overexpressed in 
prostate cancer up to 1000 fold and is not secreted from the prostate epithelium, it 
was introduced as an attractive target for prostate cancer imaging and treatment (21, 
22). 
PSMA radiopharmaceuticals are used in a cutting-edge clinical medicine field 
for diagnostic imaging or therapeutic purpose (23-30). Many of the developed PSMA 
targeting molecules are small molecular type. Glutamate-Urea-Lysine 
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(GUL) derivatives is one of the PSMA targeting molecule and also commonly used 
as a radiolabeled molecule (31).    
 With the drawback of rapid blood clearance of small molecular type GUL, as 
mentioned earlier, albumin-based PSMA targeting nanoparticle has recently been 
proposed in view of therapeutic application to elongate blood circulation time and to 
increase radiotracer accumulation in the tumor tissue (21, 32-34). Umbricht et al. 
reported that PSMA ligands comprising an albumin binder, 177Lu-PSMA-ALB 56 
showed better therapeutic effects on PSMA-positive tumor xenografts of mice 
compared with small molecular 177Lu-PSMA 617 did (32). In another report by Kuo 
et al., the albumin-binder-conjugated 177Lu-HTK01169 showed 3.7-fold higher peak 
uptake and 8.3-fold higher overall radiation dose to PSMA-positive tumor 
xenografts compared with 177Lu-PSMA 617 did (21).  








The purpose of this study was to compare radiation exposure to the normal 
tissues between single peptide radiotracer, 64Cu-GUL and albumin-based 
nanoparticle radiotracer, 64Cu-albumin-GUL by biodistribution and voxel-based 
absorbed dose measurement using PET/CT image to simulate the maximum safety 
dose for their clinical application in TRT in the future.  
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Materials and methods 
 
Preparation of 64Cu-GUL 
 NOTA-GUL kit (35) vial was purchased and added with 64CuCl3 in 0.1 M HCl 
solution (1.0, 2.0 or 3.0 mL). The vial was vigorously mixed for 1 min and then was 
incubated at room temperature for 10 min. The radiolabeling efficiency was 
evaluated by instant thin layer chromatography-silica gel (ITLC-SG) with 0.1 M 
Na2CO3 as the eluent and detected with a radio-TLC scanner. 
 
Conjugation of albumin with ADIBO-NHS 
Human Albumin Fraction V was purchased from MP Biomedicals (Aurora, Ohio, 
USA). Azadibenzocyclooctyne-NHS ester (ADIBO-NHS) and 2,2',2''-(2-(4-(3-(3-
azidopropyl)thioureido)benzyl)-1,4,7-triazonane-1,4,7-triyl)triacetic acid (N3-
NOTA) were purchased from FutureChem (Seoul, Korea).  
The modification of albumin for conjugation of GUL and chelator on albumin 
surface was performed using previous method on paper and having slightly modify 
the procedures (36).  Albumin was dissolved in phosphate buffered saline (PBS) at 
a concentration of 10 mg/mL. ADIBO-NHS were dissolved in DMSO (1 mg/10 μL), 
and then 6 uL of ADIBO-NHS was added to albumin solution. The 7.5 molar excess 
of ADIBO group was used to make the ADIBO functionalized albumin. The reaction 
vials were incubated at room temperature for two hours. Size exclusion 
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chromatography was done using a PD-10 column with PBS as the mobile phase.  
Collected albumin conjugates were examined using Nano-drop for concentration 
and matrix-assisted laser desorption ionization time of flight/time of flight mass 
spectrometry (MALDI-TOF/TOF MS) (MALDI TOF-TOF 5800 System, AB 
SCIEX, Framingham, MA, U.S.A) for molecular weight. 
 
Preparation of albumin-GUL conjugates 
To obtain albumin-GUL conjugate, N3-GUL (280 nmole, dissolved in PBS) was 
added to albumin-ADIBO conjugate (70 nmole/1 mL, dissolved in PBS) and 
incubated at 4°C for 1 h. Albumin-GUL conjugate was further purified using the PD-
10 desalting column eluted with PBS.      
Collected albumin-GUL conjugates were examined using Nano-drop for 
concentration and using MALDI TOF-TOF 5800 System (AB SCIEX, Framingham, 
MA, U.S.A) for molecular weight. 
 
Preparation of 64Cu-albumin-GUL 
64Cu containing vial was blow dried by a dry N2 gas above the sample in a fume 
hood for 1h. After the vial is completely dried, 100 µl of 1M sodium acetate buffer 
(pH 5.3) was added to reach pH 5, followed by the addition of N3-NOTA (15 nmole). 
The mixture was incubated at 70 ºC for 10 min on a heat block. Radiolabeling 
efficiency was determined using radio-instant thin layer chromatography-silica gel 
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(ITLC-SG) after the radiolabeling procedure with 0.1 M citric acid (Rf of 
radiolabeled N3-NOTA = 0.4-0.5; Rf of free radioisotope = 0.9-1.0; Rf of radiolabeled 
albumin conjugate = 0.0-0.1) as the mobile phases.   







Fugure 1. Schematics of 64Cu-albumin-GUL synthesis   
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Serum stability test 
Human serum was filtered with syringe filter, hydrophilic (0.2μm, Sartorius 
stedim biotech., Bohemia, NY, U.S.A). Filtered human serum was mixed with 64Cu-
albumin-GUL and 64Cu-GUL were incubated 37℃ in a shaking incubator. At each 
time points (0.5, 1, 4, 24 and 48 h) after the probes mixed with human serum, the 
mixtures were analyzed using ITLC-SG with 0.1 M citric acid for 64Cu-albumin-
GUL and with 0.1 M Na2CO3 for 64Cu-GUL as the solvent. The radiochemical purity 
was checked by radio TLC chromatogram and a percentage of value at Rf = 0.0–0.1. 
 
In vitro competitive binding assay  
PSMA positive cell line, LNCaP cell (provided by National Cancer Center, Korea) 
was grown in the IMDM (Thermo Fisher Scientific, Gibco 12440-053). LNCaP cell 
was harvested at an 80% confluence, plated in 24 well plates at approximately 1 × 
106 cells/well and incubated overnight in a humidified incubator at 37 ˚C with 5% 
CO2. 68Ga-GUL was diluted in serum-free cell culture medium containing 0.5% 
bovine serum albumin. Serial diluted samples each 0.5mL were added to the cells in 
the presence of 0.5mL cold GUL (250 μM) and incubated for 1h in a humidified 
incubator at 37 ˚C, 5% CO2. After 1h, the medium was aspirated and the pellet was 
washed twice. 1mL of 1 % sodium dodecyl sulfate in phosphate buffer saline solution 
was added to the plates and gently mixed. The mixture was transferred to 5mL 
disposable plastic test tubes and their radioactivity was counted with a gamma-
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counter. The binding curve was drawn in the excel sheet and the total estimated 
concentration of binding sites, Bmax and the equilibrium dissociation constant, Kd 
values were calculated by curve fitting.  
.  
Animal PET/CT imaging  
The Institutional Animal Care and Use Committee at Seoul National University 
approved all animal care and experiments for this research. Specific pathogen-free 5 
to 7-week-old normal male balb/c mice were used for this study. The first group of 
mice was injected with 64Cu-GUL and second group of mice was injected with 64Cu-
albumin-GUL via tail vein injection after anesthetization by 2% isoflurane at 1.5-2 
L/min oxygen flow for 5 minutes.  
Dedicated small animal positron emission tomography/computed tomography 
(PET/CT) scanner (eXplore VISTA, GE Healthcare, WI) was used for PET imaging. 
Dynamic whole body PET imaging (2 beds) was started right after radiotracer 
injection and was acquired for 60 minutes with the energy window 250-700 keV. 
Those 60 minutes were consists of 5 sec/bed × 6, 30 sec/bed × 5, 90 sec/bed × 3, 
150 sec/bed × 5, 10 min/bed × 2. CT scanning was followed after PET scanning 
was finished without moving mouse. The CT acquisition was performed for 
attenuation map and for anatomical information using 140 uA tube current and 40 
kVp. We further acquired serial PET images at 4.5 hour and 20 hour for 5 min per 




Figure 2. Scheme of animal experiment of PET imaging 
This is schematic diagram of animal experiment of PET imaging. Dynamic images 
of mouse (2beds) were acquired for initial 60 minutes, consists of 5 sec/bed × 6, 
30 sec/bed × 5, 90 sec/bed × 3, 150 sec/bed × 5, 10 min/bed × 2. Static images 
of mouse (2beds) were followed with acquisition for 5min per bed at 4.5 h and 20h, 







When acquisition of the initial 1hr dynamic PET/CT images finished, urines of 
the mice in each group were examined by a radio-TLC scanner. Urine of mouse with 
64Cu-GUL injection was evaluated by ITLC-SG with 0.1 M Na2CO3 and urine of 
mouse with 64Cu-albumin-GUL injection was evaluated by ITLC-SG with 0.1 M 
citric acid. 
 
Phantom PET/CT imaging 
Uniform phantom was prepared using 50mL disposable plastic tube containing 
64Cu. The volume of phantom was 58.7mL and the concentration of activity was 6.9 
× 104 Bq/mL the same PET/CT machine, mentioned above was used for 1hr static 
PET/CT image (1bed) of the phantom. CT scanning was followed after PET scanning 
was finished without moving it, with the same CT current and voltage parameters. 
 
Image reconstruction  
The PET data were reconstructed using a two-dimensional ordered-subsets 
expectation maximum (OSEM) algorithm with attenuation correction using CT, 
random correction and scatter correction was used for PET image reconstruction. 
The reconstructed PET images had the matrix size of 175 × 175 × 61 and voxel size 
of 0.3875 × 0.3875 × 0.775 mm3.  
The CT data were reconstructed using FeldKamp algorithm with a matrix size of 
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1018 × 1018 × 872 and voxel size of 0.06 × 0.06 × 0.06 mm3.  
The CT and PET DICOM images were post processed using AMIDE tool to 
match the voxel size of 0.39 × 0.39 × 0.39 mm3 for MC simulation. The voxel 
intensity of PET images was given in the standardized uptake value (SUV). 
 
Measurement of correction factor  
The volume of interest (VOI) was drawn over the reconstructed uniform 
phantom image and mean SUV of VOI) was measured, which was corrected to 
Bq/cc. Correction factor for the conversion of calculating activity concentration 
from SUV (PET image) into actual activity concentration was calculated by 
dividing the initial activity concentration (Bq/cc) in the phantom to the measured 
activity concentration (Bq/cc).  
 
PET image-based biodistribution  
VOIs were manually drawn over the major organs of the mice (brain, heart, 
lungs, liver, and kidneys), slice by slice on CT images at different time points with 
the help of the co-registered CT and PET images. Mean SUVs obtained by VOIs of 
the organs were converted into actual activity concentration (Bq/cc) with the help 
of correction factor. The activity of each organ (Bq) was normalized to the total 
injected dose (%ID) of each radiotracers and the total injected dose (%ID) vs. time 
curves and the total injected dose per gram (%ID/gm) were presented. The 
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cumulated activity (MBq.hr) in each organ was calculated by the trapezoidal 
summation of the area under curve (AUC) of time activity curve. The residence 
time was calculated from the formula of cumulated activity divided by injected 
activity of 64Cu-GUL or 64Cu-albumin-GUL in each mouse. 
 
GATE Monte Carlo simulation  
GATE v.7.0, has been used for simulations to calculate absorbed dose in this 
study (37). GATE which has been extended for dosimetry simulations is based on 
the Geant4 toolkit, a well-established code for radiation transport (38). This version 
of GATE makes use of Geant4 v. 9.6.3. The size of PET and CT images of mice were 
resampled to match the voxel dimensions (0.3875 mm × 0.3875 mm × 0.775 mm). 
The CT image (attenuation map) and the PET image (activity distribution map) were 
used as voxelized phantom and voxelized source respectively as the inputs for GATE 
simulation. ImageRegularParametrisedVolume option of GATE was chosen for 
voxelized phantom using mouse CT image and 18F ion source type of Geant4 v. 9.6.3 
was used for all simulations in this study. Standard electromagnetic physics package 
of GATE MC, which includes photoelectric effect, Compton, bremsstrahlung and 
positron-electron annihilation, was used during all simulations. GATE was run with 
Mersenne Twister (39) random number generator where the energy cuts and variance 
reduction techniques were not applied in the physical processes. The simulation was 
conducted in an in-house computing cluster with a 60-core CPU and 80 GB of RAM 
to reduce the simulation time. A separate simulation for each PET frame was 
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performed with the corresponding biodistribution and PET frame duration. During 
each simulation, the statistical uncertainties were kept below 2% at the voxel-level.  
 
Voxel-based absorbed dose calculations using GATE MC (40) 
The outputs of the GATE simulations are the energy deposition (Edep) map, dose 
distribution map (dosemaps), the number of hits and the local statistical uncertainty. 
GATE MC contains a mechanism, named DoseActor, which stores the absorbed dose 
in a given volume in a 3D matrix (41). The deposited energy [J] in each voxel was 
extracted using DoseActor mechanism from all the Dose maps with the help of VOIs 
previously drawn on CT and PET images. The absorbed dose in a voxel was 
subsequently calculated by dividing the voxel energy with the voxel mass obtained 
in this study. The absorbed dose in the organ was finally calculated by summing all 
the voxel doses with that organ. We then calculated dose rates (Gy/hr) in the organs 
from each PET frame by dividing the absorbed dose with the respective simulation 
time. The dose rate vs. time curves were plotted to measure the total absorbed dose 
in each organ using AUCs. The estimated absorbed dose at voxel-level was 
normalized to the injected activity of 64Cu-GUL or 64Cu-albumin-GUL in each 





Figure 3. Schematics of GATE MC simulation for absorbed dose estimation at 





Radiolabeling of NOTA-GUL and albumin-GUL using click chemistry 
Radiolabeling was performed immediately before the scheduled experiments 
considering half-lives of radioisotopes. Labeling efficiencies of 64Cu with NOTA-
GUL or albumin-GUL were measured by radio-TLC scanner and they both were 





Figure 4. Radiolabeling efficiencies of 64Cu-GUL and 64Cu-albumin-GUL  





Determination of the conjugation number  
Molecular weights of the collected ADIBO-albumin and albumin-GUL were 
measured by MALDI TOF/TOF MS to estimate the number of attached ADIBO-
NHS and GUL moieties on albumin. Molecular weights of the albumin, ADIBO-
albumin and albumin-GUL were 66475, 68980 and 70164, respectively. The 
estimated number of ADIBO conjugation was about 7, which is considered as degree 
of functionalization (DOF). Number of GUL attached on the albumin was calculated 






 Figure 5. Determination of the conjugation number  
The estimated number of ADIBO conjugation was about 7, which is considered as 
degree of functionalization. The number of GUL attached on the albumin was 





Serum stability test 
The radiochemical purities of both radiotracers, checked by radio TLC 









Figure 6. Serum stability test 
The radiochemical purities of both radiotracers were over 95% up to 48 h.   
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In vitro affinity test 
Bmax and Kd values were calculated through in vitro competitive binding assay. 
As the concentration of 64Cu-GUL was increased, the radioactivity of LNCaP was 
increased in the presence of another PSMA binding small molecule, which means 
PSMA-specific binding of 64Cu-GUL was increased. Bmax and Kd values were 





Figure 7. In vitro affinity test 
(A) PSMA-specific binding of 64Cu-GUL was increased as the concentration of 
64Cu-GUL was increased in the presence of PSMA inhibitor.  
(B) Bmax and Kd values, calculated through in vitro competitive binding assay, 
were 0.0672 and 9.337 × 10-9, respectively.   
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In vivo animal study 
Serial PET images were obtained after tail vein injection of 64Cu-GUL and 64Cu-
albumin-GUL using a dedicated animal PET/CT scanner. Maximum intensity 
projection PET images after 64Cu-GUL and 64Cu-albumin-GUL injection via tail vein 
were demonstrated (Figure 8, 9). The initial dynamic images for 60 minutes were 
reconstructed into 21 frame images (Figure 8B, 9B). Static PET images were 
obtained for 5 minute per bed for 2bed at 4.5 h and 20 h and for 10 minute per bed 
for 2bed at 48 h.  
Accumulation of 64Cu-GUL was noted dominantly in the kidneys and then bladder 
sequentially within 60 minutes, which means early urinary excretion. Accumulation 
of 64Cu-albumin-GUL is noted mainly in the blood inside the heart and in the liver, 
and this distribution persists after 60 minute. Minimal radioactivity is noted in the 







Figure 8. In vivo PET results of 64Cu-GUL 
(A) Maximum intensity projection PET images after 64Cu-GUL injection via tail 
vein up to 48 h were demonstrated. The 1st image is the summation images 
during 0~60 minutes. 
(B) Maximum intensity projection PET images of 21 frames during the initial 60 
minute dynamic study were demonstrated. Accumulation of 64Cu-GUL is 









Figure 9. In vivo PET results of 64Cu-albumin-GUL 
(A) Maximum intensity projection PET images after 64Cu-albumin-GUL injection 
via tail vein up to 48 h were demonstrated. The 1st image is the summation 
images during 0~60 minutes. 
(B) Maximum intensity projection PET images of 21 frames during the initial 60 
minute dynamic study were demonstrated. Radioacitivity of 64Cu-albumin-GUL 
is mainly localized in the blood inside the heart and in the liver. This distribution 





Urine TLC results of the mouse after 1hr 64Cu-GUL injection shows almost 
identical peak with that of the 64Cu-GUL (Figure 10). However, urine TLC results of 
the mouse after 1hr 64Cu-albumin-GUL injection shows minimal peak at the location 







Figure 10. Urine TLC results after 1 hr of 64Cu-GUL injection  
Urine of the mouse with 64Cu-GUL injection was examined by ITLC-SG with 0.1 M 
Na2CO3 after acquisition of the initial 1hr dynamic PET/CT images. Urine TLC 



























Figure 11. Urine TLC after 1 hr of 64Cu-albumin-GUL injection 
Urine of the mouse with 64Cu-GUL injection was examined by ITLC-SG with 0.1 M 
citric acid after acquisition of the initial 1hr dynamic PET/CT images. Urine TLC 
result shows minimal peak at the location of the free 64Cu.  
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PET image-based biodistribution 
For quantification, the reconstructed uniform 64Cu phantom image in that the activity 
was already known was used to calculate the correction factor for 64Cu and it was 
4.28. The reconstructed voxel intensity of PET images obtained from our PET/CT 
system was given in SUV. The SUVs are converted into activity using correction 
factor.  
TACs of the brain, blood, lungs, liver and kidneys were obtained (Figure 12-14). 
Blood activity was calculated from the blood activity in the heart, multiplied by 1.4.  
Activity of 64Cu-GUL in the kidneys was increased until 10 minute and then 
decreased rapidly. Other than that, the peaks of 64Cu-GUL in the brain, blood, lungs, 
were found within 1 minute and steadily decreased. The peaks of 64Cu-albumin-GUL 
in all of the major organs were also found within 1 minute, but led to the plateaus 
unlike 64Cu-GUL. Activity of 64Cu-albumin-GUL only in the liver slightly increased 
again at the 4.5 h. 
The cumulated activities and residence times in the brain, heart wall, blood in the 
heart, lungs, liver and kidneys were described in the table 1 and Figure 15. All organs 
of the mouse treated with 64Cu-albumin-GUL had higher cumulated activity than that 
of the mouse treated with 64Cu-GUL. Liver showed the highest accumulation of 
radioactivity in both groups. The next highest accumulation of radioactivity was 
found in the lungs of the mouse treated with 64Cu-albumin-GUL and in the kidneys 












































Mouse 1 Mouse 2 Mean  Mouse 1 Mouse 2 Mean 
Brain 0.33 0.38 0.36 6.41 5.53 5.97 
Heart wall 0.14 0.10 0.12 4.06 3.94 4.00 
Blood in 
Heart 
0.50 0.40 0.45 20.1 20.0 20.0 
Lungs 0.64 0.79 0.71 18.3 19.8 19.1 
Liver 6.95 5.34 6.14 98.0 112 105 











Voxel-based absorbed dose 
Dose maps were simulated by GATE MC simulation method (Figure 16). Dose-rate 
vs. time graphs of the brain, heart wall, lungs, liver and kidneys were 
demonstrated in figure 17. Normalized dose rates (mGy/MBq.hr) that is expressed 
as dose rate per unit radioactivity of the administered radiotracer were plotted in 
figure 18 and 19. 
The voxel-based absorbed doses (mGy/MBq) of the 5 organs in the mouse with 
64Cu-GUL or 64Cu-albumin-GUL injection are presented in the table 2 with voxel 
size of each VOIs (n). The graphs of those were drawn and compared between 
groups and within the each group (Figure 20, 21 and 22).  
All major organs of the mouse that treated with 64Cu-albumin-GUL had higher 
absorbed doses than those of the mouse that treated with 64Cu-GUL. Overall, the 
absorbed dose of the liver due to 64Cu-albumin-GUL was the highest (134.25 ± 
22.39 mGy/MBq). In the mouse with 64Cu-GUL injection, kidneys had the highest 
absorbed dose. However, absorbed dose of the kidneys due to 64Cu-albumin-GUL 






Figure 16. Representative images of the dose maps (Gy/voxel) by GATE Monte 























Figure 18. Normalized dose rates (mGy/MBq.hr), expressed as dose rate per 

















Table 2. Voxel-based absorbed dose (mGy/MBq) in the major organs 
  
organ 
  64Cu-GUL 64Cu-albumin-GUL 
  Mouse 1 Mouse 2 Mean Mouse 1 Mouse 2 Mean 
Brain 
absorbed dose 1.09 1.43 1.26 23.72 18.9 21.33 
voxel size of VOI  6760 6034   6871 6195   
Heart 
wall 
absorbed dose  2.69 2.24 2.46 108.99 85.9 97.42 
voxel size of VOI  1101 1060  1078 930  
Lungs 
absorbed dose  2.41 3.08 2.74 106.57 92.1 99.34 
voxel size of VOI 5860 5804   5789 5753   
Liver 
absorbed dose 6.83 5.9 6.36 150.2 116.8 133.48 
voxel size of VOI 21878 20312  20420 18591  
Kidneys 
absorbed dose 13.22 21.69 17.46 128.99 85.72 107.35 




Figure 20. Comparison of voxel-based absorbed dose (mGy/MBq) in major 
organs between two groups 
All major organs of the mice with 64Cu-albumin-GUL injection had higher 
absorbed doses than those of the mice with 64Cu-GUL injection. Overall, the 






Figure 21. Comparison of voxel-based absorbed dose (mGy/MBq) in major 





Figure 22. Comparison of voxel-based absorbed dose (mGy/MBq) in major 
organs within the group of 64Cu-albumin-GUL injection 




Absorbed dose of 64Cu-GUL and 64Cu-albumin-GUL were compared in mice to 
estimate radiation exposure to normal tissue. In the results, all of the brain, blood 
or heart wall, lungs, liver and kidneys show higher residence time and absorbed 
dose when treated with 64Cu-albumin-GUL. The most important strategy for 
successful TRT is to deliver lethal dose to the tumor without unduly affecting 
healthy tissue. Because of the variable PSMA expression of the individual’s prostate 
tumor cell, it is better for radiopharmaceutical dose to be selected as high as possible. 
But in any case, it should be under the maximum safety dose. Therefore, 
foreknowing safety dose is important. 
In this study, voxel-based dosimetry using MC simulation was used to calculate 
absorbed dose. Till now, very few preclinical voxel-based dosimetry studies of real 
mouse PET images have been reported, especially using 64Cu (42). T Xie et al. 
reported that cross-absorbed S-value of 64Cu is the smallest among positron 
emitters (11C, 13N, 15O, 18F, 68Ga, 86Y and 124I) and is significantly lower to the non-
adjacent target organs (43). Because of complex decay scheme of 64Cu, different 
types of radiation contribute to the S-values. Photons and x-rays, electron and 
positron contribute to the total cross-absorbed S-value for 64Cu. While contribution 
of positrons to the total self-absorbed S-value is over 92% for 18F, it is less than 
40% for 64Cu. Instead, electron contributes more than 50% to the self-absorbed S 
value for 64Cu. Miller WH et al. reported that 64Cu emits lower energy betas and 
subsequently, has higher self-absorption in the source organ among other beta 
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emitters such as 90Y, 188Re, 166Ho and 149Pm (44). Still, mouse organs are small and 
they are located close to each other with dimensions comparable to beta ranges, even 
for beta of lower energy. Therefore, small variation in mice anatomy can lead 
significant differences in absorbed dose measurement. Since the voxel-based 
analysis using MC simulation reflects the individual anatomy variation, there is 
strength in this situation. 
Generally, one concern of using single peptide for TRT is high dose delivered to 
the kidneys. In this study, 64Cu-GUL show highest absorbed dose in the kidneys 
among the measured organs.  
Data about TRT-related nephrotoxicity are limited (5). There are reports about 
acute radiation nephritis with uremia and pronounced tubular damage after 
administration of 90Y-labeled anticarcinoembryonic antigen Fab fragments (9–15 
MBq) and 225Ac-labeled antibodies (13 kBq) in mice (45, 46). In human, Barone et 
al. found that the risk of renal dysfunction was increased with a kidney biological 
effective dose more than 45 Gy in a group of 18 patients treated with 90Y-
DOTATOC (47). Bodei et al. reported a 28 Gy bioeffective dose threshold in 
patients with preexisting risk factors for renal disease in dosimetry study of 28 
patients treated with 90Y-DOTATOC or 177Lu DOTATATE (48).  
In clinical studies with PSMA-targeting TRT, Okamoto et al. reported a mean 
absorbed organ doses of 5.3 ± 1.6 Gy (0.72 Gy/GBq) for kidneys as a critical 
organ in patients with 177Lu-PSMA I&T, which indicates that on average a 
cumulative activity of 40 GBq of 177Lu-PSMA I&T is safe when 28 Gy is the dose 
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limit (49). Kabasakal et al. reported a calculated absorbed dose was 0.88 ± 0.40 
mGy/MBq for kidneys in patients treated with 177Lu-PSMA 617 with 30 GBq of 
dose limit (50). Kuo et al. reported 17.1-fold higher radiation dose to kidneys in a 
preclinical dosimetry study in mice treated with albumin-conjugated 177Lu-PSMA 
617 derivatives when comparing with those of 177Lu-PSMA 617 (21).  
Compatible with this, the current study also shows higher cumulated activity 
and higher absorbed dose of the kidneys treated with 64Cu-albumin-GUL than those 
treated with 64Cu-GUL. Despite of minimal renal excretion of albumin-
nanoparticle, still it gives higher radiation exposure to the kidneys than single 
peptide does, probably due to its longer blood circulation.  
Liver show the highest absorbed dose among the measured organs when treated 
with 64Cu-albumin-GUL. Based on the principle, the organ to whole body 
radioactivity ratio in mice would be equal to that in human, biodistribution of 
radiopharmaceuticals obtained in mice has been converted to human 
biodistribution data by multiplying a ratio of total body weight of the mice/total 
body weight of adult (51, 52). This formula cannot be applied as it is to calculate 
absorbed dose because different anatomy and size of organs between mouse and 
human affecting cross-absorbed dose. But if it is applied only to estimate 
approximate human absorbed dose to catch a trend, the estimated absorbed doses 
of 64Cu-albumin-GUL in the heart wall, lungs, liver and kidneys are 0.033 
mGy/MBq, 0.034 mGy/MBq, 0.046 mGy/MBq and 0.037 mGy/MBq, respectively, 
when 25g was used for total body weight of the mice and 73 kg was used for total 
body weight of male adult. The estimated absorbed doses of 64Cu-GUL in those 
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organs were 0.008 mGy/MBq, 0.0009 mGy/MBq, 0.002 mGy/MBq and 0.006 
mGy/MBq, respectively, which is minimal compared to those of 64Cu-albumin-
GUL. 
In external radiation data, tissue tolerance dose of a 5% rate of complications 
within 5 years (TD5/5) are 45Gy for heart wall, 17.5 Gy for lungs, 30Gy for liver 
and 23 Gy for kidneys (53). If these are used for dose limit although it is 
inappropriate that the tissue tolerable dose from external radiation therapy data 
applies directly to TRT, not liver but lung is a dose-limiting organ among them for 
64Cu-albumin-GUL with average a cumulative activity of 514 GBq.   
More important concern when using albumin-nanoparticle is radiation exposure 
to bone marrow caused by its extended blood retention time. Blood activity is very 
closely related to absorbed dose to the bone marrow. To measure bone marrow 
activity, blood or plasma activity concentration is used under the assumption of that 
extracellular fluid in the marrow spaces has the same activity concentration as 
plasma, meaning that the red marrow to plasma activity concentration ratio is a 
constant (54, 55). A standard time-independent value of 0.19 has been 
conventionally used for red marrow to plasma activity concentration ratio (54, 55). 
Alternatively, 0.32-0.36 is typically used using whole blood (55, 56). The 
maximum tolerated dose for red marrow in human are as low as 1-2 Gy, and it is 
far lower than that of others (17). Taking all of these into account, there is a high 
probability that bone marrow will become the critical organ rather than liver or 
lungs when treated with albumin-conjugated nanoparticle. 
In dosimetry studies with single peptide GUL, this will be of less concern. 
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Kabasakal et al. reported that the radiation-absorbed dose delivered to the bone 
marrow was significantly lower than those of kidneys with the calculated radiation 
dose to bone marrow of 0.03 ± 0.01 mGy/MBq in patients treated with 177Lu-
PSMA 617 (50). Kuo et al. reported that 30.4-fold higher radiation dose to bone 
marrow with albumin-conjugated 177Lu-PSMA 617 derivatives was calculated 
compared with those of 177Lu-PSMA 617 (21). 
In view of TRT, albumin-GUL conjugates have double-sidedness of long blood 
circulation leading higher tumor uptake and limiting maximum safety dose, which 
should be taken into consideration for optimal TRT. Recently, it is possible to 
manipulate in vivo biodistribution of albumin nanoplatform as the researchers 
intended by controlling the DOF attached on the albumin (36). As number of 
conjugation is increased, liver accumulation is increased and blood pool is decreased. 
In other words, liver and blood pool has an opposing relationship according to the 
DOF, probably how fast the particle is eliminated by liver. Therefore, to find the 
optimal DOF that makes the balance of liver and blood pool activity can be lead to 







Comparison of absorbed dose to the normal tissues between single peptide and 
albumin nanoparticle targeting PSMA was made using voxel-based dosimetry 
methods. 64Cu-albumin-GUL can be efficiently synthesized via click chemistry 
technique as a PSMA-targeting nanoplatform with high labeling yield and stability. 
Along with longer residence time, the calculated absorbed dose of 64Cu-albumin-
GUL was higher than that of 64Cu-GUL in all organs of the brain, heart wall, liver 
and kidneys. In view of safety therapeutic radiation dose, albumin-GUL conjugates 
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국  문  초  록 
 
PET 영상 기반 생체 분포 및 흡수 선량 
측정을 통한 64Cu-GUL 와 64Cu-





분자의학 및 바이오제약학과 
 
전립선특이막항체 표적 핵종 치료가 전립선 암 치료의 최첨단 임상 
분야에 도입되었다. 표적 핵종 치료의 효과는 주로 종양과 정상 조직의 
총 흡수 선량에 달려 있다. 따라서, 종양 치사량 이상이고 최대 안전 
선량 이하인 방사 선량의 범위가 최대한 정확하게 결정되어야 한다. 
장기 수준의 선량 측정과 관련된 여러 가지 제한 때문에, 표적 핵종 
치료 동안 보다 정확한 흡수 선량을 평가하기 위해서는 복셀 기반의 
선량 측정법이 필수적이게 되었다. 본 연구의 주요 목적은 복셀 기반의 
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선량 측정법을 사용하여 전립선특이막항체 표적 펩타이드와 알부민 나노 
입자의 정상조직에 대한 방사선량을 비교하는 것이다. 
본 연구에서는 전립선특이막항체를 표적하는 방사선 표지 펩타이드 
(64Cu-GUL)와 알부민 나노 입자 (64Cu-albumin-GUL)를 합성하고, 
정상 쥐의 PET/CT 영상을 가지고 직접 GATE MC 시뮬레이션방법을 
이용하여 복셀 기반 선량 측정을 수행하였다. 
   
64Cu-albumin-GUL이 64Cu-GUL과 비교하여 뇌, 심장벽, 폐, 간 
그리고 신장의 흡수 선량이 모두 높았다. 64Cu-GUL은 주로 신장에 
축적되었으며, 64Cu-albumin-GUL는 간에 축적되었다. 혈액 저류 시간 
역시 64Cu-albumin-GUL 가 64Cu-GUL 보다 높았다.  
단일 펩타이드 64Cu-GUL은 신장의 방사선량이 높고, 알부민 나노 
입자 64Cu-albumin-GUL은 긴 혈액 순환으로 인해 정상조직에 대한 
방사선량을 전반적으로 증가시키므로 최적의 표적 핵종 치료 계획을 
위해서는 이를 고려해야 할 것이다.  
 
주요어: 복셀 기반 선량 측정법, GATE, 64Cu-GUL, 64Cu-알부민-GUL, 
PET/CT, 전립선특이막항체 
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